Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Bristol-Myers Squibb and Oncolys BioPharma Enter Global Licensing Agreement for Investigational HIV Compound

By Pharmaceutical Processing | December 20, 2010

Bristol-Myers Squibb Company and Oncolys BioPharma Inc., a
privately held biotechnology company based in Japan, announced today that the
companies have signed a definitive agreement under which Bristol-Myers Squibb
will acquire exclusive worldwide rights to manufacture, develop and
commercialize festinavir, a once-a-day, orally available nucleoside reverse transcriptase
inhibitor (NRTI) in Phase II development for HIV.

“Bristol-Myers Squibb has been dedicated to helping patients
prevail over HIV for more than two decades and is committed to the ongoing
discovery, development and delivery of medicines to fight HIV/AIDS globally”

Under the terms of the agreement, Oncolys may receive up to
$286 million including upfront, development, regulatory and sales milestone
payments. Oncolys is also eligible to receive tiered royalties on the worldwide
product sales.

“Bristol-Myers Squibb has been dedicated to helping patients
prevail over HIV for more than two decades and is committed to the ongoing
discovery, development and delivery of medicines to fight HIV/AIDS globally,”
said Brian Daniels, senior vice president, Development. “The profile of festinavir
offers the possibility of improvement in the safety of long-term HIV treatment,
an area of significant unmet medical need.”

President & CEO of Oncolys BioPharma, Mr. Yasuo Urata
said, “I’m honored to have completed this license agreement with Bristol-Myers
Squibb for the development and commercialization of festinavir. For many years
I have been working for the development of medicines in the fight against
HIV/AIDS, and I’m convinced that festinavir has the possibility to be a potent
and effective NRTI with a promising resistance profile. Also festinavir’s
once-daily dosage is essential for treating HIV patients worldwide.”

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE